Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1865 • ACR Convergence 2025
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis
Hanlin Yin¹, Wanyi Lin², Zhangyi zhao¹, Chenhan Jia¹ and Liangjing Lu¹, ¹Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China (People's Republic), ²Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: Antinuclear antibodies (ANA) are detected in over 95% of systemic sclerosis (SSc) patients. Compared to cutaneous subtype classification, autoantibody-based stratification more accurately predicts survival,…
Abstract Number: 2396 • ACR Convergence 2025
A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
Gerber Gomez¹, Yipeng Cheng², Kristiana Nita², Michael Hausmann³, Christian Fischer¹ and Yasemin Ataman-Önal³, ¹Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ²AliveDx, Edinburgh, United Kingdom, ³AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Detection of relevant autoantibodies is key in the identification of autoimmune connective tissue diseases (CTD). The evaluation of multiple autoantibodies for extended serological profiling…
Abstract Number: 2599 • ACR Convergence 2025
Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
Beatriz Vellón-García¹, Sagrario Corrales-Díaz-Flores², MARIA ANGELES AGUIRRE ZAMORANO³, Ismael Sanchez-Pareja³, Laura muñoz-Barrera³, Tomás Cerdó³, Pedro Seguí-Azpilcueta⁴, Christian Merlo², Maria del carmen abalos-aguilera², Nuria Barbarroja⁵, Rafaela Ortega-Castro⁶, José-Antonio Gonzalez-Reyes⁷, Alejandro Escudero-contreras², Chary López pedrera⁸, Jose manuel Villalba⁹ and Carlos Pérez Sánchez¹⁰, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁴Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA³)., Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁹Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:1- Characterize the circulating metabolomic signature in APS patients; 2- Investigate the role of hepatic involvement in the pathophysiology of APS;…
Abstract Number: 0278 • ACR Convergence 2025
Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Xiwei Yang¹, Shae Chambers², Aretha On¹, Hammad Ali², Touraj Khosravi³, Lais Lopes Almeida Gomes², Rui Feng⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy subclassified as classic (CDM) and clinically amyopathic (CADM). It can involve myositis-associated (MAA) and myositis-specific (MSA) autoantibodies.…
Abstract Number: 0859 • ACR Convergence 2025
Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
Bruna Mazetto Fonseca¹, Srilakshmi Yalavarthi², Katarina Kmetova², NaveenKumar Somanathapura³, Cyrus Sarosh⁴, Kavya Sugur⁵, Wenying Liang⁶, Yu (Ray) Zuo³, Richard W. Lieberman⁶ and Jason S. Knight³, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ³University of Michigan, Ann arbor, MI, ⁴University of Michigan, Temperance, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁶University of Michigan, Ann arbor
Background/Purpose: Neutrophil extracellular traps (NETs) are webs of chromatin and proteases (e.g., neutrophil elastase) that have been implicated in antiphospholipid syndrome (APS)-associated thrombosis; however, their…
Abstract Number: 0911 • ACR Convergence 2025
A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models
Hang Su¹, Lulu Li¹, Zenglin Pei¹, Barry Duplantis², Yuhao Wang², Yi Li¹ and Quan Yu¹, ¹Ailux, Shanghai, China (People's Republic), ²Ailux, Boston, MA
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome are characterized by elevated levels of pathogenic autoantibodies that drive inflammation. The…
Abstract Number: 1391 • ACR Convergence 2025
Assessment of Anti-SSA/Ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Mala Masson¹, Bettina Cuneo², Philip Carlucci³, Peter Izmirly⁴, Justin Brandt⁵, Colin Phoon⁶, Ashley Roman⁶, Amit Saxena⁷, Michael Belmont⁵, Christina Penfield⁶, Young Mi Lee⁶, Julie Nusbaum⁵, Andrew Rubenstein⁶, Elena Sinkovskaya⁸, Alfred Abuhamad⁸, Gary Satou⁹, Whitnee Hogan¹⁰, Anita Moon-Grady¹¹, Lisa Howley¹², Mary Donofrio¹³, Stephanie Levasseur¹⁴, Miwa Geiger¹⁵, Sonal Owens¹⁶, Kristopher Cumbermack¹⁷, Jyothi Matta¹⁸, Gary Joffe¹⁹, Christopher Lindblade²⁰, Caitlin Haxel²¹, Katherine Kohari²², Joshua Copel²², James Strainic²³, Tam Doan²⁴, Conisha Holloman²⁴, Stacy Killen²⁵, Theresa Tacy²⁶, Michelle Kaplinski²⁶, Nalani Sachan⁶, Nicola Fraser⁶, Robert Clancy¹⁴ and Jill Buyon⁶, ¹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ²University of Arizona College of Medicine, Tucson, AZ, ³New York University School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁸Eastern Virginia Medical School, Norfolk, VA, ⁹University of California Los Angeles, Los Angeles, CA, ¹⁰University of Utah, Salt Lake City, UT, ¹¹University of California San Francisco, San Francisco, CA, ¹²Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹³Children's National Hospital, Washington, DC, ¹⁴Columbia University, New York, NY, ¹⁵Mount Sinai School of Medicine, New York, NY, ¹⁶University of Michigan, Ann Arbo, MI, ¹⁷University of Kentucky, Lexington, KY, ¹⁸University of Louisville, Louisville, KY, ¹⁹Perinatal Associates of New Mexico, Albuquerque, NM, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Vermont Children's Hospital, Burlington, VT, ²²Yale University, New Haven, CT, ²³UH Rainbow Babies, Cleveland, OH, ²⁴Baylor College of Medicine, Houston, TX, ²⁵Vanderbilt University, Nashville, TN, ²⁶Stanford University, Stanford, CA
Background/Purpose: For women with Sjögren's disease, the risk of Fetal Atrioventricular Block (fAVB) is a critical aspect in pregnancy counseling. To date, the most reliable…
Abstract Number: 1931 • ACR Convergence 2025
COSMOS Prevalence of aTTP in SLE
Nisha Sapkota¹, Yevheniia Andriushchenko², Saadia Malik², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse manifestations, including thrombotic thrombocytopenic purpura (TTP), a life-threatening hematologic disorder. The pathogenesis of…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2630 • ACR Convergence 2025
The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies
Camila Hernández-Blanco¹, Philip Carlucci², Peter Izmirly³, Jessica Dai⁴, Mala Masson⁵, Michael Belmont¹, Amit Saxena⁶, Jane Salmon⁷, Justin Brandt¹ and Jill Buyon⁸, ¹NYU Langone Health, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, Tenafly, NJ, ⁵NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁶Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁷Hospital for Special Surgery, New York, NY, ⁸NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) primarily affects females of childbearing age and increases the risk of adverse pregnancy outcomes (APOs), particularly in non-White individuals and…
Abstract Number: 0281 • ACR Convergence 2025
Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Anja Srpcic¹, Manca Ogric¹, Sasa Cucnik¹, Sergej Pirkmajer², Katja Lakota¹ and Katja Perdan Pirkmajer¹, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…
Abstract Number: 0860 • ACR Convergence 2025
Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository
Maria Efthymiou¹, Ibrahim Tohidi-Esfahani², Veronica Venturelli¹, Maria Tektonidou³, Vittorio Pengo⁴, Diana Parades-Ruiz⁵, Ware Branch⁶, Maria Gerosa⁷, Cecilia Nalli⁸, Esther Rodriguez Almaraz⁹, Michelle Petri¹⁰, Ricard Cervera¹¹, Olga Amengual¹², Danieli Andrade¹³, Rohan Willis¹⁴, Maria Laura Bertolaccini¹⁵, Doruk Erkan¹⁶ and Hannah Cohen¹⁷, ¹University College London, London, United Kingdom, ²University of Sydney, Syndey, Australia, Sydney, Australia, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵Biobizkaia Health Research Institute, Barakaldo, Spain, Barakaldo, Spain, ⁶University of Utah Health Sciences Center, Salt Lake City, UT, ⁷University of Milan, Milano, Italy, ⁸ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁹Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Hospital Clinic Barcelona, Barcelona, Spain, ¹²Hokkaido University Graduate School of Medicine, Sapporo, Japan, Sapporo, Japan, ¹³University of Sao Paulo, São Paulo, São Paulo, Brazil, ¹⁴University of Texas Medical Branch, Galveston, TX, ¹⁵King's College London, London, United Kingdom, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Dysregulation in the protein C anticoagulant pathway, more specifically acquired resistance to activated protein C (APCr) and antibodies against protein C (anti-PC), has been…
Abstract Number: 0942 • ACR Convergence 2025
Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
Jennifer Nicholson¹, Maria Ossa-Echeverri¹, Arpitha Haranahalli Shivarudrappa¹, Mark Lusco¹, Maria de la Luz Garcia-Hernandez², John Looney¹, Jennifer Anolik³ and Javier Rangel-Moreno¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Though immune targeted therapies have improved outcomes in lupus nephritis, a significant number of patients experience renal damage and even progression to end stage…
Abstract Number: 1471 • ACR Convergence 2025
Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study
Amir Daneshvar¹, Julia Wajsberg¹, Chelsea Guan¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker², Meghan Gump¹ and Omer Pamuk³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement. A rare but life-threatening hyper-inflammatory hematological complication of SLE is hemophagocytic lymphohistiocytosis…
Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Carmen Secada-Gómez¹, Ligia Gabrie-Rodriguez², Hector Ulloa-Alvarado³, Giuliano Boselli⁴, Camilo Veloza-Morales⁵, Diana Prieto-Peña⁶, juan Irure-Ventura⁷, Marcos López-Hoyos⁸ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁴Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁵Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…

« Previous Page
1
…
3
4
5
6
7
…
37
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].